Ewopharma AG
Ewopharma AG is a privately held Swiss pharmaceutical commercialization company that provides end-to-end market access, licensing, and distribution services for partner pharma companies across 15+ Central Eastern European countries and Switzerland, employing 350+ people.
- Company typePrivate
- Founded1959
- HeadquartersSchaffhausen, Switzerland
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Ewopharma AG does
Ewopharma AG is a privately held, owner-managed pharmaceutical commercialization and market access company headquartered in Schaffhausen, Switzerland, founded in 1959 as the successor to M.R. Leclerc & Co. The company operates a direct local distribution model across 15+ Central Eastern European (CEE) countries plus Switzerland, employing 350+ people through local subsidiaries staffed by Medical Sales Representatives with medical or pharmacy degrees. Its core business is serving as the CEE/Switzerland commercial partner for international pharmaceutical companies, providing end-to-end market access services including marketing authorization procedures, pricing and reimbursement negotiations, regulatory and pharmacovigilance compliance, and field sales.
The company's revenue is generated through two streams: (1) licensing and distribution agreements with pharmaceutical partners — including Biogen (Benepali, Flixabi, Spinraza), Eisai (Lenvima, Halaven, Kisplyx), Dr. Falk Pharma (Salofalk, Ursofalk, over 20-year partnership), BioGaia (probiotics, since 2007), CStone Pharmaceuticals (sugemalimab, 2024 deal worth up to $51.3M in upfront/milestones), and Can-Fite BioPharma (Piclidenoson, Namodenoson); and (2) proprietary product sales including Revalid (hair and skin care brand, launched 1992 in Switzerland), Isoprinosine (antiviral acquired via Newport Pharmaceuticals in 2011), and Viruxan (antiviral consumer health brand). Therapeutic focus areas are gastroenterology, immunology, neurology, and oncology.
Strategically, Ewopharma has pursued a programmatic M&A and licensing agenda in recent years, acquiring Neomed s.r.o. in 2023 and AllergyCare Ltd. in 2024, while securing new oncology partnerships with CStone and Can-Fite and expanding into cardiovascular medtech via a 2024 distribution agreement with Translumina for drug-eluting stents and drug-coated balloons in Bulgaria. The company is controlled by the Staub and Wohlgemuth families, has no institutional investors, and is operationally active with subsidiaries in every CEE market it serves.
Ewopharma AG firmographics
Firmographics- Name
- Ewopharma AG
- Legal name
- Ewopharma AG
- Website
- https://ewopharma.com
- Company type
- Private
- Founded year
- 1959
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Ewopharma AG is a privately held Swiss pharmaceutical commercialization company that provides end-to-end market access, licensing, and distribution services for partner pharma companies across 15+ Central Eastern European countries and Switzerland, employing 350+ people.
- Ownership category
- akta.pro rank
Ewopharma AG industry classification
Industry- Product category
- Pharmaceutical Commercialization and Distribution
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Pharmaceutical Distributors (HLAIAJAB)
- akta.pro secondary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Ewopharma AG is headquartered
LocationHeadquarters
- HQ city
- Schaffhausen
- HQ country
- Switzerland
- HQ region
- Europe
Offices18 records
Markets served
Ewopharma AG business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Licensing and Distribution of Partner Products: Ewopharma generates revenue by securing exclusive licensing and distribution rights for pharmaceutical products in CEE and Switzerland. They commercialize partner brands alongside their own proprietary products (Revalid, Isoprinosine) through local subsidiaries in 15+ countries.
- Proprietary Product Sales: Revenue from sales of own brands including Revalid (hair and skin care developed in Switzerland) and Isoprinosine (antiviral drug acquired with Newport Pharmaceuticals in 2011).
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Ewopharma AG product offering
Product offeringCore offering
Ewopharma is a pharmaceutical commercialization partner that secures exclusive licensing and distribution rights for partner pharmaceutical products in Central Eastern Europe and Switzerland. Through local subsidiaries and a field force of medically trained Medical Sales Representatives, it manages the full go-to-market process including marketing authorization, pricing and reimbursement negotiations, regulatory and pharmacovigilance compliance, marketing, and sales. It also markets its own proprietary brands including the Revalid hair and skin care line, the Isoprinosine antiviral, and Viruxan.
Product overview
Ewopharma AG is a pharmaceutical marketing and commercialization company serving as a bridge to pharmaceutical markets in Central Eastern Europe and Switzerland. The company operates two core business units: pharmaceuticals (Rx) and consumer health. In pharmaceuticals, the company focuses on four key therapeutic areas: gastroenterology, immunology, neurology, and oncology. The company markets both proprietary brands (Revalid® for hair and skin care, Isoprinosine® and Viruxan for antiviral treatment) and partner brands from pharmaceutical companies including Dr. Falk Pharma (Salofalk, Ursofalk), Biogen (Benepali, Flixabi, Spinraza), Eisai (Halaven, Lenvima, Kisplyx), CStone (Cejemly/sugemalimab), and Can-Fite (Namodenoson). The company also distributes BioGaia probiotic products for digestive health. Beyond product distribution, Ewopharma provides comprehensive market access services including regulatory support, pricing negotiations, and commercialization expertise.
Differentiator
Problem solved
Functional benefit
Brands
- Revalid: Proprietary product line for holistic hair and skin care developed in Switzerland in 1992.
- Isoprinosine
- Viruxan
Products and services
- Market Access and Commercialization Services End-to-end pharmaceutical market access service covering marketing authorization procedures, complex pricing and reimbursement negotiations, regulatory and pharmacovigilance requirements, and marketing and promotion in CEE and Switzerland, sold to pharmaceutical partner companies.
- Revalid Proprietary Swiss-developed holistic hair and skin care product line addressing hair loss and skincare, combining Swiss medical expertise with scientific research.
- Isoprinosine Proprietary antiviral drug with immunomodulatory properties indicated as adjunctive treatment for viral infections, fully owned via Newport Pharmaceuticals acquisition.
- Viruxan Proprietary antiviral brand in Ewopharma's consumer health portfolio.
- Salofalk (mesalazine) Distribution Distribution and commercialization of Dr. Falk Pharma's mesalazine anti-inflammatory for inflammatory bowel disease across Eastern Europe.
- Ursofalk (ursodeoxycholic acid) Distribution Distribution and commercialization of Dr. Falk Pharma's bile acid medication for liver and gallbladder disorders across Eastern Europe.
- BioGaia Probiotic Products Distribution Distribution, registration, sales, and marketing of BioGaia science-backed probiotic products for digestive health in 15+ CEE countries.
- Benepali (etanercept) and Flixabi (infliximab) Distribution Distribution of Biogen's anti-TNF alpha biosimilars Benepali and Flixabi for immunology indications including autoimmune disorders across the CEE network.
- Spinraza (nusinersen) Distribution Distribution of Biogen's Spinraza breakthrough therapy for spinal muscular atrophy (SMA) patients across the CEE network.
- Halaven (eribulin mesylate) and Lenvima/Kisplyx (lenvatinib) Distribution Distribution of Eisai's Halaven breast cancer treatment and Lenvima/Kisplyx oncology kinase inhibitors for thyroid cancer, hepatocellular carcinoma, endometrial cancer, and renal cell carcinoma in CEE.
- Cejemly (sugemalimab) Distribution Commercialization of CStone's anti-PD-L1 monoclonal antibody Cejemly for metastatic non-small cell lung cancer (NSCLC) in Switzerland and 18 CEE countries.
- Namodenoson Distribution Distribution of Can-Fite BioPharma's Namodenoson A3 adenosine receptor agonist being developed for hepatocellular carcinoma, NASH, and pancreatic cancer in CEE and Switzerland.
Companies that use Ewopharma AG
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles2 records
Ewopharma AG technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Ewopharma AG partnerships and signals
Strategic signalPartnerships
21 partnerships are on record, tiered minor and core.
- TransluminaminorExclusive distribution agreement for advanced cardiovascular solutions in Bulgaria. Ewopharma licensed to distribute Translumina's drug-eluting stents (DES) and Blue Medical's drug-coated balloon (DCB) technologies.
- CStone PharmaceuticalscoreStrategic commercial collaboration for sugemalimab (anti-PD-L1 monoclonal antibody) in Switzerland and 18 CEE countries. Ewopharma gained commercial rights for all EU member countries (Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia) and non-EU countries (Albania, Bosnia & Herzegovina, Kosovo, North Macedonia, Moldova, Montenegro, Serbia). CStone received up to $51.3 million in upfront payment and additional considerations for regulatory and sales milestones.
- Can-Fite BioPharmacoreDistribution agreement for Piclidenoson (psoriasis) and Namodenoson (hepatocellular carcinoma, NASH, pancreatic cancer) in CEE countries and Switzerland. Ewopharma paid US$2.25 million upfront with up to US$40.45 million in regulatory and sales milestones, plus 17.5% royalties on net sales. Expanded in 2024 to include pancreatic cancer indication.
- EisaicoreCommercial partnership for Lenvima (lenvatinib) in 9 CEE countries within approved indications of differentiated thyroid cancer and unresectable hepatocellular carcinoma. Ewopharma responsible for pricing, reimbursement, marketing, and distribution. Eisai supplies product and provides training and support. Also extended bexarotene distribution to all CEE countries.
- BioGaia ABcoreDistribution partnership for probiotic products established in 2007. Collaboration grown to include registration, distribution, sales, and marketing of BioGaia products in 15 CEE countries. Partnership renewed in 2026 for continued distribution across 15+ countries.
- Dr. Falk PharmacoreLong-standing partnership beginning over 20 years ago with Salofalk and Ursofalk products. Collaboration has grown to include marketing, sales, and regulatory support of an extensive Dr. Falk portfolio across Eastern Europe. Partnership renewed in 2025 for another decade.
- BiogencorePartnership for anti-TNF biosimilar drugs (Benepali/etanercept and Flixabi/infliximab) and Spinraza (nusinersen) for spinal muscular atrophy patients. Products distributed through Ewopharma's CEE network.
- AcistminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- DentinoxminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- BraccominorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- DesitinminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- GaldermaminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- PharmacosmosminorPartner brand providing state-of-the-art intravenous iron therapies. Listed in gastroenterology portfolio.
- Stallergenes GreerminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- Johnson & JohnsonminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- Advanz PharmaminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- NeobiomicsminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- EumedicaminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- SalvatminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- VianexminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
- VerforaminorPartner brand listed in Ewopharma's portfolio of pharmaceutical partners.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Ewopharma AG competitors and assessment
Company assessmentBroad incumbents
- Sandoz Group AG: Recently spun-off Novartis generics and biosimilars business with strong European and CEE footprint. Comparable in biosimilars-led CEE strategy and therapeutic overlap (anti-TNF, immunology) with Ewopharma's Biogen biosimilars portfolio.
- Teva Pharmaceutical Industries Ltd. Global generics and specialty pharma leader with significant CEE commercial presence. Comparable in broad CEE distribution and specialty pharma reach, though far larger and with materially different economics.
- Recordati S.p.A. Italian specialty pharma group with established CEE subsidiaries and focus on gastroenterology, cardiology and rare diseases. Comparable therapeutic overlap (gastroenterology presence via Salofalk-adjacent products) and CEE distribution model, though broader and larger.
Direct peers
- Stada Arzneimittel AG: German-headquartered specialty and generics pharma group with deep CEE distribution and commercialization presence. Highly comparable to Ewopharma as a Western-rooted pharma company commercializing through local subsidiaries across Central and Eastern Europe.
- Gedeon Richter Plc. Hungarian-headquartered specialty pharma with strong CEE presence in CNS, women's health and biosimilars. Comparable in CEE commercialization scale, therapeutic focus, and owner-controlled governance model.
- Polpharma SA: Polish pharma group combining generics, specialty pharma and OTC across CEE. Comparable in CEE manufacturing/distribution footprint and therapeutic breadth overlapping with Ewopharma's gastroenterology, neurology and immunology categories.
- Egis Pharmaceuticals PLC: Hungarian pharma group serving CEE markets with branded generics and specialty products across cardiovascular, oncology and CNS. Comparable to Ewopharma in CEE-centric go-to-market and portfolio combining owned and partnered brands.
- Zentiva Group: European generics and specialty pharma with historic CEE roots (Czech/Slovak) now operating pan-European. Directly comparable in CEE go-to-market, branded specialty portfolio, and combination of owned + in-licensed products.
- KRKA, d. d., Novo mesto: Slovenian-headquartered generic and specialty pharma group operating across CEE. Comparable in territorial focus (Slovenia + CEE), therapeutic breadth (gastroenterology, oncology, CNS), and the model of combining owned brands with partner/distribution arrangements.
Emerging players
- Alvotech hf. Icelandic biosimilars developer commercializing through regional partners including for CEE. Comparable as a partner-of-Ewopharma-type counterparty and as a biosimilars-focused player in the same therapeutic categories Ewopharma distributes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Ewopharma AG social profiles
Digital presenceEwopharma AG financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ewopharma AG leadership team
Management profileNumber of profiles
Profiles8 records
Ewopharma AG subsidiaries and ownership
Company hierarchySubsidiaries3 records
Ewopharma AG funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ewopharma AG M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ewopharma AG
What does Ewopharma AG do?
Ewopharma is a pharmaceutical commercialization partner that secures exclusive licensing and distribution rights for partner pharmaceutical products in Central Eastern Europe and Switzerland. Through local subsidiaries and a field force of medically trained Medical Sales Representatives, it manages the full go-to-market process including marketing authorization, pricing and reimbursement negotiations, regulatory and pharmacovigilance compliance, marketing, and sales. It also markets its own proprietary brands including the Revalid hair and skin care line, the Isoprinosine antiviral, and Viruxan.
Is Ewopharma AG a public or private company?
Ewopharma AG is a private company. It is classified as family owned and is currently operating.
When was Ewopharma AG founded?
Ewopharma AG was founded in 1959. It employs 251 to 500 people.
Where is Ewopharma AG based?
Ewopharma AG is headquartered in Schaffhausen, Switzerland, in the Europe region.
How does Ewopharma AG make money?
Two revenue lines are on record. Licensing and Distribution of Partner Products are the primary driver. The others are proprietary Product Sales.
Who are Ewopharma AG's main competitors?
Broad incumbents on record are Sandoz Group AG, Teva Pharmaceutical Industries Ltd. and Recordati S.p.A.. Direct peers are Stada Arzneimittel AG, Gedeon Richter Plc., Polpharma SA, Egis Pharmaceuticals PLC, Zentiva Group and KRKA, d. d., Novo mesto. Alvotech hf. is listed as an emerging player.
Does Ewopharma AG have an API?
No public API is recorded for Ewopharma AG.
What industry is Ewopharma AG in?
Ewopharma AG's product category is Pharmaceutical Commercialization and Distribution. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 424210 and its SIC code is 5122.